Accelerate Diagnostics Reports 2018 Fourth Quarter and Full-Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Accelerate Diagnostics (AXDX) Reports In-Line Q4 EPS
February 19, 2019 4:03 PM ESTAccelerate Diagnostics (NASDAQ: AXDX) reported Q4 EPS of ($0.41), in-line with the analyst estimate of ($0.41).
Added 133 commercially contracted instruments, compared to 22 in the fourth quarter of 2017.Net sales of $1.8 million, compared to $2.1 million in the fourth quarter of 2017, a decrease attributable to lower capital sales mix as customers... More